Sabra Health Care REIT, Inc. Announces Fourth Quarter 2024 Earnings Release Date and Conference Call; Declares Common Dividend

Business Wire
04 Feb

TUSTIN, Calif., February 03, 2025--(BUSINESS WIRE)--Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that it will issue its 2024 fourth quarter earnings release on February 19, 2025, after the close of trading.

A conference call with a simultaneous webcast to discuss the 2024 fourth quarter results will be held on Thursday, February 20 at 10:00 a.m. Pacific Time. The dial-in number for U.S. participants is 888-880-4448. For participants outside the U.S., the dial-in number is 646-960-0572. The conference ID number is 1382596.

The webcast URL is https://events.q4inc.com/attendee/595686468. A digital replay of the call will be available on our website at www.sabrahealth.com.

Also, on February 3, 2025, Sabra’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on February 28, 2025, to common stockholders of record as of the close of business on February 14, 2025.

About Sabra

Sabra Health Care REIT, Inc., a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (a "REIT") that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250203257375/en/

Contacts

Investor & Media Inquiries: 1-888-393-8248 or investorinquiries@sabrahealth.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10